Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT07765888RecruitingPhase 3
Tilrekimig for moderate-to-severe eczema
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
Birmingham, AlabamaAges 12 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT07864701RecruitingPhase 1/Phase 2
Study of an experimental drug for MYC-positive advanced cancers
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07445087Recruiting
Takhzyro for hereditary angioedema in teenagers and adults
This study is for people in South Korea with hereditary angioedema. It looks at how well the drug Takhzyro works and how safe it is for teenagers and adults who are already using it or will start using it.
Suwon, Gyeonggi-doAges 12 years+ - NCT07825064RecruitingPhase 2
Cevostamab combination after CAR T-cell therapy for multiple myeloma
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
GreifswaldAges 18 years+ - NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Duarte, CaliforniaAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT02504853Recruiting
Study food allergy patterns and genetics over time
This study follows people with food allergy and some closely related or healthy people to learn how food allergy (and related conditions) develops over time. It may help researchers find causes and better ways to predict and treat food allergy.
Bethesda, MarylandAges 1 day–99 years - NCT07200089RecruitingPhase 1
IL-7 treatment after CAR-T therapy for multiple myeloma
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
St Louis, MissouriAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT07354074RecruitingPhase 2
Study of asciminib for children with Ph+ CML
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
New Brunswick, New JerseyAges 1–18 - NCT00004317RecruitingPhase 4
Treating Congenital Toxoplasmosis With Three Medications
This study tests a combination of three medications (pyrimethamine, sulfadiazine, and leucovorin) to treat toxoplasmosis—a parasitic infection passed from mother to baby during pregnancy. The goal is to see if early treatment prevents serious complications in infected infants.
Chicago, IllinoisAges Any age - NCT02527486Recruiting
Airways registry study for people with COPD symptoms
This registry collects information from people with COPD (and sometimes overlapping asthma-COPD features) to better understand breathing problems and airways behavior. It may help researchers learn which patterns match different symptom types, without necessarily using a new drug.
Seongnam-si, Gyeonggi-doAges 20–90 - NCT03023371Recruiting
National registry for IgG4-related disease in China
This study is a registry that collects information about people diagnosed with IgG4-related disease (a specific immune-related condition). It helps doctors better understand the condition and how it looks and behaves in real life.
Beijing, Beijing MunicipalityAges Any age - NCT02259556RecruitingPhase 1/Phase 2
CAR T treatment for CD30-positive lymphomas after standard therapies
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Beijing, Beijing MunicipalityAges 16–80 - NCT02869529Recruiting
Chronic lymphatic leukemia patient database study
This study collects information from people diagnosed with chronic lymphatic leukemia. It may help doctors better understand the disease, track patient needs, and improve future care.
Marseille, Bouches-du RhôneAges 18–95 - NCT02869555Recruiting
Study of people with multiple myeloma in a patient database
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
Marseille, Bouches-du RhôneAges 18–95
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.